Exelon Articles
Focus On Exelon For Alzheimer's Disease
14 August 1997
1st Approval For Novartis' Exelon; 2nd For Revasc
7 August 1997
Novartis Unveils Strong Product Pipeline
1 July 1997
Novartis To File Exelon Worldwide This Month
20 March 1997
Eisai's Aricept Available In USA, Its First Market
27 January 1997
No Hidden Surprises From US FTC For Birth Of Novartis
6 January 1997
Sandoz' Alzheimer's Drug; International Data Revealed
2 December 1996
Galanthamine Enters Ph III In USA For Alzheimer's
28 October 1996
Europe Stock Comment
5 August 1996
First Efficacy Data With Sandoz' Exelon
5 August 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
FDA Panel Backs Cellcept For Acute Rejection
10 April 1995
SANDIMMUN SET FOR DECLINE, SAYS ANALYST
27 June 1994
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
